Immediate-release versus extended-release guanfacine for treatment of attention-deficit/hyperactivity disorder

American Journal of Pharmacy Benefits

Volumn 5, Issue 4, 2013, Pages

  Sikirica, Vanja ^b   Xie, Jipan ^a   He, Tony Lizhang ^a   Erder, M Haim ^b   Hodgkins, Paul ^b   Yang, Hongbo ^a   Samuelson, Thomas ^a   Wu, Eric Q ^a  

^a ANALYSIS GROUP   (United States)

^b SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; GUANFACINE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AMBULATORY CARE; ARTICLE; ATTENTION DEFICIT DISORDER; COHORT ANALYSIS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; EXTENDED DRUG RELEASE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; IMMEDIATE DRUG RELEASE; MAJOR CLINICAL STUDY; MEDICATION POSSESSION RATIO; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84882668292     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Increasing prevalence of parentreported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. MMWR. 2010;59(44):1439-1443.
2. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32(6):631-642.
3. Goksøyr PK, Nøttestad JA. The burden of untreated ADHD among adults: the role of stimulant medication. Addict Behav. 2008;33(2):342-346.
4. Adler LA. Epidemiology, impairments, and differential diagnosis in adult ADHD: introduction. CNS Spectr. 2008;13(8)(suppl 12):4-5.
5. Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010; 177(3):299-304.
6. Doshi JA, Hodgkins P, Kale J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990-1002.
7. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195-206.
8. Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007-1022.
9. Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):102-116.
10. Duong S, Chung K, Wigal SB. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD. Expert Opin Drug Metab Toxicol. 2012;8(5): 543-552.
11. Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012;85(1):45-58.
12. Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther. 2012;29(5):385-400.
13. Signorovitch J, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940-947.
14. Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/ hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):130-137.
15. Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat. 2008;4(3):499-506.
16. Posey DJ, McDougle CJ. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev. 2007;13(4):465-474.
17. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074.
18. Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253-1262.
19. Vivek K, Fanda AK, Varshney S, et al. Extended release pharmaceutical compositions of guanfacine hydrochloride. US Patent Application 20110217373. September 8, 2011.
20. Humana Inc. Provider drug search results. http://apps.humana.com/prescription_benefits_and_services/execreq.asp?processcode=3&srcsite=physician&productid=4&ndc=54092051902&view=c. Accessed September 25, 2012.
21. Aetna, Inc. Pharmacy clinical policy bulletins-Aetna non-Medicare prescription drug plan-attention deficit hyperactivity disorder (ADHD) agents. http://www.aetna.com/products/rxnonmedicare/data/2012/CNS2012/adhd_2012.html. Accessed September 25, 2012.
22. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
23. Erder MH, Signorovitch JE, Setyawan J, et al. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ. 2012;15(6):1078-1087.
24. Rubino M, Summers KH, Puenpatom A, Fu C, Ohsfeldt RL, Ben-Joseph RH. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. J Manag Care Pharm. 2011;17(5):367-376.
25. Bureau of Labor Statistics, US Department of Labor. Measuring the price change for medical care in the CPI. http://www.bls.gov/cpi/cpifact4.htm. Accessed September 10, 2012.
26. Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of oncea-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):I93-I101.
27. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408-414.
28. Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010;26(4):977-989.
29. Sallee FR. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad Med. 2010;122(5):78-87.
30. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin. 2003;19(7): 619-626.
31. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300-303.